Avita Medical AI Stock Analysis
Avita Medical (51KA) AI Stock Analysis
Avita Medical
(Frankfurt:51KA)
No summary available
Avita Medical (51KA) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 429.78M
- Dividend Yield
- ―
- Average Volume (3M)
- 944
- Price to Earnings (P/E)
- -14.5
- Beta (1Y)
- 1.36
- Revenue Growth
- 11.04%
- EPS Growth
- 38.35%
- Country
- Germany
- Employees
- 226
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Avita Medical Business Overview & Revenue Model
Company Description
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harves...
Avita Medical Earnings Call Summary
The call was strongly positive. Revenue growth accelerated, RECELL adoption expanded, Cohealyx grew, PermeaDerm produced favorable clinical and economic results, gross margin improved, cash use declined substantially, liquidity strengthened through the additional $10 million credit-facility draw, and full-year guidance was raised for the second consecutive quarter. The main challenges were flat international RECELL and PermeaDerm revenue, continued net losses, lower margins for newer products, ongoing hospital adoption reviews, and some uncertainty around seasonal Q3 volume; these issues were outweighed by the reported operating and financial improvements.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
AVITA raised full-year 2026 revenue guidance to $92 million-$94 million from $86 million-$89 million, representing approximately 28%-31% growth over 2025, with $93 million at the midpoint, compared with approximately $35 million in 2022 and a compound annual growth rate of approximately 28% over four years; the guidance implies Q4 revenue of approximately $24.9 million-$26.9 million and approximately 30% growth for the full year over 2025, while the company remains on track to achieve cash flow breakeven in the fourth quarter. RECELL gross margin is currently expected to remain between 85% and 90% over the coming quarters. For 2027, management is not providing formal guidance but said it expects to grow at a rate that it has been growing, keep operating expenses flat, and does not see headcount going up significantly, with commissions having some variability as revenue goes up.
Avita Medical Risk Analysis
Avita Medical disclosed 39 risk factors in its most recent earnings report. Avita Medical reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksAvita Medical Peers Comparison
Overall Rating
BVS66Neutral
SNWV48Neutral
TELA48Neutral
IART40Underperform
SRTS36Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| BVS | 66Neutral | $942.04M | 12.98 | 27.23% | ― | 3.87% | 623.68% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SNWV | 48Neutral | $16.17M | 5.93 | 113.13% | ― | -0.61% | ― |
| TELA | 48Neutral | $36.11M | -1.27 | 425.91% | ― | 1.46% | 15.79% |
| IART | 40Underperform | $1.13B | 88.02 | 1.24% | ― | 0.84% | ― |
| SRTS | 36Underperform | $54.32M | -3.64 | -34.09% | ― | -53.40% | -1719.88% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:51KA | Avita Medical Ltd | 15.10 | 11.94 | 377.85% | |
| IART | Integra Lifesciences | 14.77 | 2.73 | 22.67% | |
| SNWV | Sanuwave Health Inc. | 1.78 | -31.78 | -94.70% | |
| SRTS | Sensus Healthcare, Inc. | 3.41 | -1.05 | -23.54% | |
| TELA | Tela Bio, Inc. | 0.94 | -0.17 | -15.23% | |
| BVS | Bioventus, Inc. | 10.99 | 3.42 | 45.18% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.